DSP Plans Japan Trials On Targeted Cancer Drug Of BBI Subsidiary
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma said it plans to begin clinical trials in Japan for two oral cancer drugs, BBI608 and BBI503, considered the world's first to target cancer stem cells.